Form 4: IN8BIO CEO Amends Warrant Terms, Acquires Pre-Funded Warrants

IN8BIO CEO William Tai-Wei Ho amended existing warrants and acquired pre-funded warrants to purchase common stock, according to a recent SEC filing.

Summary

• On April 27, 2025, IN8BIO CEO William Tai-Wei Ho amended the terms of outstanding Series B warrants, reducing the exercise price from $1.50 to $0.45 per share.
• The CEO also acquired 81,967 new Series B warrants with the amended exercise price.
• On May 1, 2025, Ho surrendered 81,967 Series A warrants in exchange for an equal number of pre-funded warrants with an exercise price of $0.0001 per share.
• These pre-funded warrants have no expiration date and are exercisable at any time after issuance, subject to certain limitations.
• The original warrants were granted on December 13, 2023, as part of a unit purchase at $1.22 per unit, which included one share of common stock, one Series A warrant, and one Series B warrant.

Sentiment

Score: 6

Explanation: The document itself is neutral, detailing warrant transactions. The sentiment is slightly positive as the CEO's actions could be interpreted as a sign of confidence, but it's primarily an administrative filing.

Positives

• The CEO's acquisition of pre-funded warrants could signal confidence in the company's future prospects.
• The reduced exercise price of the Series B warrants may make them more attractive to the holder.

Future Outlook

The document does not contain explicit forward-looking statements, but the warrant amendments and exchanges suggest ongoing adjustments to the company's capital structure.

Industry Context

Warrant modifications and pre-funded warrant issuances are common financial tools used by companies, particularly in the biotech sector, to manage their capital structure and provide incentives to investors and executives.

Comparison to Industry Standards

• Warrant exercise price reductions are sometimes seen in situations where the stock price has underperformed, making the original warrants less attractive.
• Pre-funded warrants are often used by smaller companies to raise capital quickly, as they allow investors to pay the exercise price upfront, providing immediate cash flow to the company.
• Comparable companies in the biotech space, such as Celldex Therapeutics or Ziopharm Oncology, have also utilized warrants and other equity-linked securities as part of their financing strategies.

Stakeholder Impact

• Shareholders may be impacted by the potential dilution from the exercise of the warrants.
• The warrant amendments could affect the perceived value of the company's equity.

Key Dates

Keywords

IN8BIO, William Tai-Wei Ho, warrants, pre-funded warrants, SEC Form 4, amendment, exercise price, beneficial ownership